Liver Disease Diagnostics Market by Diagnosis Technique, End-user

Description

List of Tables

[194 Pages Report] The Liver Disease Diagnostics Market size was estimated at USD 9.94 billion in 2023 and expected to reach USD 11.09 billion in 2024, at a CAGR 12.76% to reach USD 23.05 billion by 2030.

The liver disease diagnostics market encompasses all technologies, products, and services dedicated to detecting and monitoring various liver conditions, including hepatitis, cirrhosis, liver cancer, and non-alcoholic fatty liver disease. The primary goal is to promote early detection, accurate staging, and effective management of liver-related diseases. The rising prevalence of liver diseases, increased awareness and preventive approaches, and improvements in healthcare infrastructure across various regions have necessitated the adoption of liver disease diagnostics solutions. Additionally, supportive government initiatives and funding for liver disease research and management accentuate the need for liver disease diagnostics. However, liver disease diagnostics faces challenges related to the high costs of advanced diagnostic tests, discrepancies in liver disease diagnostic standards, and limited accessibility in low-resource settings. Moreover, the lack of specific biomarkers for certain liver diseases and the risks associated with invasive diagnostic procedures can hinder growth. However, key players are exploring cutting-edge developments such as non-invasive imaging technologies and biomarker discovery to circumvent technical and safety complications. Furthermore, the increasing integration of AI and ML in diagnostics, which promises enhanced accuracy and predictive analytics, also opens up new avenues for growth. Personalized medicine and genomics are also gaining traction, offering the potential for tailored diagnostic and therapeutic approaches.

KEY MARKET STATISTICS
Base Year [2023]	USD 9.94 billion
Estimated Year [2024]	USD 11.09 billion
Forecast Year [2030]	USD 23.05 billion
CAGR (%)	12.76%

Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis

A liver biopsy is a process that involves the removal of a small section of liver tissue, which is then examined under a microscope. Biopsies can be crucial in diagnosing certain liver diseases that are not detectable through blood tests or imaging and in determining the degree of liver damage. Biopsies are often recommended when it is necessary to analyze the severity of liver damage in chronic conditions such as hepatitis C or to diagnose unexplained liver abnormalities. Endoscopy for liver diagnostics most often refers to a procedure known as endoscopic retrograde cholangiopancreatography, which is used to examine the bile ducts. It can identify blockages or abnormalities connected with liver diseases. Endoscopy is typically used when there is a suspicion of diseases that affect the bile ducts or when there's a need to extract bile duct stones. Imaging techniques include ultrasound, computed tomography scan, magnetic resonance imaging, and other modalities that provide detailed pictures of the liver and can help diagnose conditions like fatty liver, tumors, and cirrhosis. Imaging is the first line of non-invasive diagnostic techniques often used when there's a need for a visual assessment of the liver structure and detection of masses. Laboratory tests help in the diagnosis of liver diseases through the analysis of blood samples. Common tests include liver enzyme tests such as the alanine transaminase (ALT) test, aspartate aminotransferase (AST) test, bilirubin tests, albumin tests, clotting tests, and viral hepatitis tests. Laboratory tests are usually the first step in diagnosing liver disease and are used for routine screening, monitoring of disease progression, and evaluating treatment efficacy.

End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure

Hospitals represent a significant end-user for liver disease diagnostics. They are typically equipped with advanced diagnostic equipment and staffed by specialized healthcare professionals. Patients with liver diseases often require immediate and comprehensive care, which hospitals are usually able to provide. This includes a series of diagnostic tests such as blood tests, imaging, and biopsies to confirm the diagnosis of conditions such as hepatitis, cirrhosis, or liver cancer. The need-based preference for hospitals is generally high due to their ability to offer a full spectrum of services from diagnosis to treatment, including emergency care, surgery, and post-operative follow-ups. The integration of diagnostic services with therapeutic care is a compelling reason for patients to choose hospital-based diagnostics. Laboratories, either standalone or those associated with clinics, specialize in the analysis of blood and tissue samples to detect liver abnormalities. Compared to hospitals, laboratories may offer more convenient locations and quicker processing times for diagnostic tests, which can result in faster results for patients and physicians. Laboratories primarily cater to the need for routine screening and blood work required for the diagnosis and monitoring of liver diseases.

Regional Insights

The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement policies for various disease conditions, thereby fuelling the growth in liver disease diagnostics. Innovations in non-invasive imaging techniques and bio-marker identification are areas where significant investments and patent applications are seen. Initiatives such as the American Liver Foundation's efforts to improve liver health reflect the sector's proactive approach. The European Union displays diverse consumer behavior due to varying healthcare systems and economic capabilities across member countries. However, the adoption of the European Association for the Study of the Liver Clinical Practice Guidelines is a key factor in standardizing liver disease diagnostics. Increased R&D expenditure and multinational collaborations, such as those within the EU Horizon 2020 program, showcase the dynamic environment of innovation in the region. APAC region shows a burgeoning need for liver disease diagnostics due to the growing prevalence of liver-related disorders, growing awareness about liver health, and government initiatives to expand healthcare facilities to marginalized communities. The adoption of digital healthcare services and solutions is also gaining traction in the APAC region, which could create new avenues of growth for the industry.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liver Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Liver Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Diagnosis Technique
- Biopsy
- Endoscopy
- Imaging
- Laboratory Tests

End-user
- Hospitals
- Laboratories

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liver Disease Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Disease Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Liver Disease Diagnostics Market?

4. What is the market share of the leading vendors in the Liver Disease Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Liver Disease Diagnostics Market?

Product Code: MRR-B9334AD6C587

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in the Prevalence of Acute and Chronic Liver Diseases
  - 5.1.1.2. Development of Government and Non-Government Awareness Programs
  - 5.1.1.3. Consumer Inclination Towards Minimally Invasive Diagnostic Systems
- 5.1.2. Restraints
  - 5.1.2.1. High Cost of Diagnostic Devices and Lack of Skilled Professionals
- 5.1.3. Opportunities
  - 5.1.3.1. Technological Advancements in Diagnostic Systems
  - 5.1.3.2. Improving Healthcare Access in Economies
- 5.1.4. Challenges
  - 5.1.4.1. Complexity Associated with Liver Diagnostic Systems
5.2. Market Segmentation Analysis
- 5.2.1. Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
- 5.2.2. End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Liver Disease Diagnostics Market, by Diagnosis Technique

6.1. Introduction
6.2. Biopsy
6.3. Endoscopy
6.4. Imaging
6.5. Laboratory Tests

7. Liver Disease Diagnostics Market, by End-user

7.1. Introduction
7.2. Hospitals
7.3. Laboratories

8. Americas Liver Disease Diagnostics Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Liver Disease Diagnostics Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Liver Disease Diagnostics Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
- 11.3.2. Stone Diagnostics to Provide Fibronostics Liver Disease Test
- 11.3.3. Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease

12. Competitive Portfolio

12.1. Key Company Profiles
12.2. Key Product Portfolio